21312-94-7

Upstream product

• 75-36-5 acetyl chloride 
• 26488-93-7 N-(5-chloro-2-hydroxyphenyl)acetamide 

Downstream Products

• 672938-01-1 2-(2-chlorophenyl)-4-(5-chloro-2-oxo-3H-benzoxazol-7-yl)-4-oxobutanoic acid 
• 672938-03-3 4-(2-chlorophenyl)-6-(5-chloro-2-oxo-3H-benzoxazol-7-yl)-4,5-dihydro-3(2H)-pyridazinone 
• 672937-99-4 2-(2-chlorophenyl)-4-(5-chloro-2-oxo-3H-benzoxazol-7-yl)-4-oxobutyronitrile 
• 672938-02-2 4-phenyl-6-(5-chloro-2-oxo-3H-benzoxazol-7-yl)-4,5-dihydro-3(2H)-pyridazinone 
• 672938-00-0 2-phenyl-4-(5-chloro-2-oxo-3H-benzoxazol-7-yl)-4-oxobutanoic acid 
• 672937-98-3 2-phenyl-4-(5-chloro-2-oxo-3H-benzoxazol-7-yl)-4-oxobutyronitrile 
• 672937-97-2 3-(2-chlorophenyl)-1-(5-chloro-2-oxo-3H-benzoxazol-7-yl)-2-propen-1-one 
• 672937-96-1 3-phenyl-1-(5-chloro-2-oxo-3H-benzoxazol-7-yl)-2-propen-1-one 

Relevant academic research and scientific papers

Investigations of new pyridazinone derivatives for the synthesis of potent analgesic and anti-inflammatory compounds with cyclooxygenase inhibitory activity

In this study we describe the synthesis of two novel 4-phenyl- and 4-(2-chlorophen-yl)-6-(5-chloro-2-oxo-3H-benzoxazol-7-yl)-3(2H)-pyridazinone derivatives (compounds 8 a and b) and their testing as inhibitors of cyclooxygenases (COX-1 and COX-2). Both compounds inhibited COX-1 (by 59% and 61% for compounds 8 a and 8 b respectively) and COX-2 (by 37% and 28% for compounds 8 a and 8 b respectively) at a concentration of 10 μM. Furthermore, we tested the analgesic and anti-inflammatory activities of the synthesized compounds in vivo by using the p-benzoquinone-induced writhing test and the carrageenan-induced hind paw edema model, respectively. Compounds 8 a and b showed potent analgesic and anti-inflammatory activities without causing gastric lesions in the tested animals.